Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of DS-6157a in Advanced Gastrointestinal Stromal Tumor
jRCT2080225089Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of DS-6157 in gastrointestinal stromal tumor (GIST), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum tolerated dose (MTD) of DS-6157a and Safety and tolerability of DS-6157a (treatment-emergent adverse events). Started Feb 2020; status: completed.
02
Drugs
DS-6157
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2080225089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225089.